News & Updates
Filter by Specialty:
Show Multimedia Only
Nivolumab bests ipilimumab in head-to-head melanoma trial
28 Oct 2025
byAudrey Abella
The final, long-term results from the phase III CheckMate 238 trial continue to show the superior recurrence-free survival (RFS) benefit of adjuvant nivolumab (NIVO) over ipilimumab (IPI) for resected stage IIIB-C or IV melanoma.
Nivolumab bests ipilimumab in head-to-head melanoma trial
28 Oct 2025
Povorcitinib passes efficacy, safety tests in phase II trial for extensive vitiligo
22 Oct 2025
byStephen Padilla
Treatment with the Janus kinase (JAK) 1 inhibitor povorcitinib results in significant repigmentation of the body and face in adult patients with extensive nonsegmental vitiligo (NSV), with an acceptable safety profile, through 52 weeks, reports a phase II study.
Povorcitinib passes efficacy, safety tests in phase II trial for extensive vitiligo
22 Oct 2025
Delgocitinib cream works wonders in chronic hand eczema
14 Oct 2025
byStephen Padilla
Application of delgocitinib cream results in significant improvements in itch, pain, and quality of life (QoL) at week 16 in adults with moderate to severe chronic hand eczema (CHE), as shown in the pooled analysis of the phase III DELTA-1 and -2 trials.